Menopause Practice Questions

Q: In a postmenopausal woman, estrogen therapy is initiated. The risk of which of the following conditions will not be increased?

Osteoporosis. **Explanation:** The correct answer is **B. Osteoporosis**. Estrogen plays a critical role in maintaining bone mineral density (BMD) by inhibiting osteoclast activity and promoting osteoblast survival. In postmenopausal women, the decline in estrogen leads to accelerated bone resorption. Therefore, initiating Estrogen Replacement Therapy (ERT) is actually **protective** against osteoporosis and reduces the risk of fractures. It is a primary indication for Hormone Replacement Therapy (HRT), not a risk. **Analysis of Incorrect Options:** * **Gallstones (A):** Estrogen increases the saturation of cholesterol in bile and decreases gallbladder motility, leading to an increased risk of cholelithiasis (gallstones). * **Endometrial Carcinoma (C):** Unopposed estrogen causes endometrial hyperplasia. In women with an intact uterus, estrogen therapy significantly increases the risk of endometrial cancer. This is why progesterone is always added (Combined HRT) for women who have not undergone a hysterectomy. * **Breast Cancer (D):** Long-term use of combined HRT (Estrogen + Progesterone) is associated with a slightly increased risk of breast cancer, as estrogen stimulates the proliferation of mammary epithelial cells. **NEET-PG High-Yield Pearls:** 1. **Indication:** The most common indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes). 2. **Uterine Status:** If the uterus is present, use **Combined HRT** (E+P). If the patient has had a hysterectomy, use **ERT** (Estrogen only). 3. **Lipid Profile:** Oral estrogen increases HDL and decreases LDL (cardioprotective effect on lipids) but increases triglycerides. 4. **Contraindications:** Undiagnosed vaginal bleeding, active thromboembolism (DVT/PE), and estrogen-dependent tumors (Breast/Endometrial CA).

Q: What is the major source of estrogen in postmenopausal women?

Peripheral conversion of androstenedione. **Explanation:** In postmenopausal women, the ovaries cease follicular activity, leading to a significant drop in estradiol levels. The primary source of estrogen shifts from direct ovarian secretion to the **peripheral conversion of androgens.** **1. Why Option A is correct:** The major circulating estrogen in menopause is **Estrone (E1)**, which is weaker than the reproductive-age estradiol (E2). This estrone is produced via the aromatization of **androstenedione** (secreted primarily by the adrenal glands and some by the ovarian stroma). This conversion occurs in peripheral tissues, predominantly in **adipose tissue** (fat), through the enzyme aromatase. **2. Why the other options are incorrect:** * **Option B:** While the adrenal glands secrete the *precursors* (androstenedione and DHEA), they do not secrete significant amounts of active estrogen directly. * **Option C:** Although the postmenopausal ovary continues to secrete small amounts of testosterone due to LH stimulation of the stroma, this is not the primary source of systemic estrogen. Testosterone is more commonly converted to estradiol, whereas androstenedione is the primary precursor for estrone. **High-Yield Clinical Pearls for NEET-PG:** * **Estrogen Potency:** Estradiol (E2) > Estrone (E1) > Estriol (E3). * **Dominant Estrogen:** In pregnancy, it is **Estriol (E3)**; in menopause, it is **Estrone (E1)**. * **Obesity Link:** Obese postmenopausal women have higher estrone levels due to increased peripheral aromatization in adipose tissue, placing them at a higher risk for **endometrial hyperplasia and carcinoma.** * **Hormonal Profile:** Menopause is characterized by Low Estrogen, Low Inhibin, and **High FSH** (FSH >40 IU/L is diagnostic). FSH rises more significantly than LH.

Q: Hormone replacement therapy is contraindicated in which of the following conditions?

Thromboembolism. **Explanation:** **1. Why Thromboembolism is the Correct Answer:** Hormone Replacement Therapy (HRT), specifically the estrogen component, is associated with a prothrombotic state. Estrogen increases the hepatic synthesis of clotting factors (II, VII, IX, X) and decreases anticoagulants like Antithrombin III and Protein S. This significantly elevates the risk of **Venous Thromboembolism (VTE)**, including Deep Vein Thrombosis (DVT) and Pulmonary Embolism. Therefore, a history of or active thromboembolic disease is an **absolute contraindication** for HRT. **2. Analysis of Incorrect Options:** * **A. Atherosclerosis:** While HRT is generally not started in women with established coronary artery disease (CAD), it is not an absolute contraindication in the same way as active VTE. According to the "Timing Hypothesis," starting HRT early in menopause may actually be cardioprotective. * **C. Osteoporosis:** This is an **indication**, not a contraindication. HRT is highly effective in preventing bone loss and reducing the risk of osteoporotic fractures in postmenopausal women. * **D. Gallstones:** While HRT can increase the risk of cholelithiasis (by increasing cholesterol saturation in bile), it is considered a **relative contraindication**. It does not carry the same immediate life-threatening risk as thromboembolism. **3. High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications for HRT:** Undiagnosed abnormal vaginal bleeding, known or suspected Estrogen-dependent tumors (Breast/Endometrial CA), active/recent Thromboembolism (DVT/PE), and active Liver disease. * **Route Matters:** Transdermal estrogen has a lower risk of VTE compared to oral estrogen because it bypasses the first-pass hepatic metabolism. * **The "Gold Standard" Indication:** The primary indication for HRT is the relief of moderate-to-severe vasomotor symptoms (hot flashes, night sweats).

Q: Which of the following is NOT true about hot flushes?

Systolic blood pressure drops during a hot flush.. **Explanation:** Hot flushes (vasomotor symptoms) are the most common symptom of the perimenopause, caused by a narrowing of the thermoregulatory window in the hypothalamus due to estrogen withdrawal. **Why Option C is the correct answer:** During a hot flush, there is a transient **increase** in both heart rate and **systolic blood pressure**, not a drop. This is due to a surge in sympathetic nervous system activity. While peripheral vasodilation occurs to dissipate heat, the compensatory cardiac output increase typically leads to a slight rise in systolic pressure. **Analysis of Incorrect Options:** * **Option A:** Hot flushes are transient episodes. They typically last between **1 to 5 minutes**, though the frequency and intensity vary significantly among women. * **Option B:** The core physiological event is **peripheral vasodilation**, particularly in the face, neck, and chest. This leads to a measurable **rise in skin temperature** (often by 1–7°C) and visible flushing. * **Option C:** As mentioned, the sympathetic surge causes a **rise in heart rate** (tachycardia), often accompanied by palpitations. **NEET-PG High-Yield Pearls:** * **Most common symptom of menopause:** Hot flushes (75% of women). * **First sign of menopause:** Shortening of the follicular phase (decreased cycle length). * **Gold Standard Treatment:** Hormone Replacement Therapy (HRT). * **Non-hormonal DOC:** SSRIs/SNRIs (e.g., Paroxetine, Venlafaxine) or Gabapentin. * **Mechanism:** Estrogen deficiency leads to low endorphin levels, which increases GnRH pulses and disrupts the hypothalamic "thermostat."

Q: A vaginal smear from an elderly woman shows atrophic changes. Which type of cells are predominantly seen in such a smear?

Basal and parabasal cells. **Explanation:** The maturation of the vaginal epithelium is directly dependent on **estrogen levels**. Estrogen promotes the proliferation and maturation of squamous cells from the basal layer up to the superficial layer. **1. Why Basal and Parabasal cells are correct:** In elderly women (postmenopausal), there is a significant decline in estrogen production. Without estrogenic stimulation, the vaginal epithelium fails to mature. The superficial and intermediate layers are lost, leaving only the **basal and parabasal cells** (the least mature layers). These cells are small, round-to-oval, with a high nuclear-to-cytoplasmic (N:C) ratio, characteristic of an **atrophic smear**. **2. Why other options are incorrect:** * **Atrophic cells:** This is a descriptive term for the overall smear pattern, not a specific histological cell type. * **Superficial cells:** These are large, flat cells with pyknotic nuclei. They predominate under high estrogen influence (e.g., mid-cycle/ovulation). * **Intermediate cells:** These represent moderate estrogenic or high progesterone influence (e.g., pregnancy or the luteal phase). While a few may be present in early menopause, they are not the predominant feature of a fully atrophic smear. **High-Yield Clinical Pearls for NEET-PG:** * **Maturation Index (MI):** Expressed as a ratio of (Parabasal : Intermediate : Superficial cells). * **Atrophy (Postmenopausal):** Shift to the left (e.g., 100:0:0). * **Ovulatory phase:** Shift to the right (e.g., 0:40:60). * **Pregnancy:** Shift to the middle (e.g., 0:95:5). * **Fern Test:** Negative in atrophic states due to lack of estrogen. * **Vaginal pH:** In menopause, the lack of glycogen (due to lack of superficial cells) leads to decreased *Lactobacillus* and an **increase in vaginal pH (>5.0)**, predisposing to atrophic vaginitis.

Q: Postmenopausal bleeding is most commonly due to:

Carcinoma cervix. **Explanation:** **Correct Answer: A. Carcinoma cervix** In the context of the Indian subcontinent and many developing nations, **Carcinoma Cervix** remains the most common cause of postmenopausal bleeding (PMB). While global textbooks (based on Western data) often cite **Atrophic Vaginitis** or **Endometrial Atrophy** as the most common causes, for the purpose of Indian competitive exams like NEET-PG, malignancy—specifically cervical cancer—is the prioritized answer due to its high prevalence and clinical significance in the region. **Analysis of Incorrect Options:** * **B. Fibroid:** Uterine leiomyomas are estrogen-dependent tumors. They typically regress after menopause due to the drop in estrogen levels. While they can cause heavy menstrual bleeding in reproductive years, they are an unlikely cause of new-onset bleeding in a postmenopausal woman. * **C. Endometriosis:** This condition involves ectopic endometrial tissue that responds to cyclic hormonal changes. Like fibroids, endometriosis usually regresses after menopause; it rarely presents as postmenopausal bleeding unless the patient is on Hormone Replacement Therapy (HRT). * **D. Genital TB:** While common in India, Genital Tuberculosis typically presents with infertility or menstrual irregularities (like oligomenorrhea or amenorrhea) in younger women. It is a rare cause of postmenopausal bleeding. **Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** For any case of PMB, the first step is a **Transvaginal Ultrasound (TVS)** to measure Endometrial Thickness (ET). * **Cut-off Value:** An ET **>4 mm** in a postmenopausal woman is an indication for an endometrial biopsy to rule out Endometrial Carcinoma. * **Global Perspective:** If "Atrophic Vaginitis" or "Atrophy" is an option and the question doesn't specify a regional context, it is statistically the most common cause worldwide. However, always rule out malignancy first.

Q: All of the following parameters increase in post-menopausal women except?

Antithrombin. **Explanation:** The post-menopausal state is characterized by a significant decline in estrogen levels, which leads to a **pro-thrombotic (hypercoagulable) state**. This shift increases the risk of cardiovascular diseases and venous thromboembolism (VTE) in older women. **1. Why Antithrombin is the Correct Answer:** Antithrombin (specifically Antithrombin III) is a natural **anticoagulant**. In the post-menopausal period, the levels of natural anticoagulants like Antithrombin III and Protein S typically **decrease** or remain unchanged, rather than increase. A decrease in these protective factors contributes to the overall increased risk of thrombosis. **2. Analysis of Incorrect Options (Factors that Increase):** * **Plasminogen Activator Inhibitor-1 (PAI-1):** Levels increase after menopause. PAI-1 inhibits fibrinolysis (the breakdown of clots), thereby promoting a pro-thrombotic environment. * **Factor VII & Fibrinogen:** These are pro-coagulant factors. Estrogen deficiency leads to an increase in the synthesis of several clotting factors, including Factor VII and Fibrinogen, which enhances blood viscosity and clot formation. **High-Yield Clinical Pearls for NEET-PG:** * **Lipid Profile Changes:** Post-menopause, there is an increase in LDL, VLDL, and Triglycerides, and a **decrease in HDL**, leading to an increased risk of atherosclerosis. * **Hormone Replacement Therapy (HRT) & Coagulation:** Oral HRT can further increase the risk of VTE by increasing Factor VII, X, and fragments of prothrombin, while decreasing Antithrombin III. * **Most Sensitive Marker for Menopause:** Elevated **FSH** (>40 IU/L) is the gold standard biochemical marker. * **Cardiovascular Risk:** Before menopause, women have a lower risk of MI than men due to the protective effects of estrogen; this advantage is lost post-menopause.

Q: A patient is at risk of estrogen-dependent carcinoma, and thus estrogen is contraindicated. To prevent vasomotor symptoms, which drug is given?

Clonidine. **Explanation:** In patients where estrogen is contraindicated (e.g., history of breast cancer, endometrial cancer, or thromboembolism), non-hormonal alternatives are required to manage vasomotor symptoms (hot flashes). **Why Clonidine is correct:** Clonidine is a centrally acting **alpha-2 adrenergic agonist**. Hot flashes are thought to be triggered by a narrowing of the thermoregulatory zone in the hypothalamus, mediated by increased noradrenergic activity. Clonidine reduces central sympathetic outflow, thereby stabilizing the thermoregulatory center and reducing the frequency and severity of hot flashes. **Analysis of Incorrect Options:** * **Tamoxifen (Option A):** This is a Selective Estrogen Receptor Modulator (SERM). While it is used in breast cancer treatment, it actually **exacerbates** vasomotor symptoms and is a common cause of hot flashes. * **Conjugated Estrogen (Option B):** This is the gold standard for menopausal symptoms but is strictly **contraindicated** in patients with estrogen-dependent carcinomas. * **Yohimbine (Option D):** This is an alpha-2 antagonist (the opposite of Clonidine). It increases sympathetic activity and would likely worsen vasomotor instability. **High-Yield Clinical Pearls for NEET-PG:** * **First-line non-hormonal treatment:** SSRIs (e.g., Paroxetine) or SNRIs (e.g., Venlafaxine) are now often preferred over Clonidine due to a better side-effect profile. * **Gabapentin:** Another effective non-hormonal option that improves sleep and reduces hot flashes. * **Tibolone:** A synthetic steroid with estrogenic, progestogenic, and androgenic properties; however, it is also generally avoided in active estrogen-dependent cancers. * **Fezolinetant:** A newer NK3 receptor antagonist specifically approved for moderate-to-severe vasomotor symptoms.

Q: A 56-year-old woman presents with hot flushes, irritability, joint pains, and insomnia. What is the most appropriate treatment?

Combined estrogen, progesterone preparations. **Explanation:** The patient is presenting with classic **vasomotor symptoms** (hot flushes) and psychological symptoms (irritability, insomnia) associated with **menopause**. **1. Why Option C is Correct:** The gold standard treatment for moderate-to-severe menopausal vasomotor symptoms is **Hormone Replacement Therapy (HRT)**. Estrogen is the most effective agent for relieving hot flushes. Since the patient is 56 years old and there is no mention of a prior hysterectomy, she is assumed to have an intact uterus. In women with a uterus, **combined estrogen and progesterone** must be given. Progesterone is added solely to prevent estrogen-induced endometrial hyperplasia and the subsequent risk of endometrial carcinoma. **2. Why Other Options are Incorrect:** * **Option A (Hysterectomy):** This is a surgical intervention for structural pathology (like fibroids or malignancy) and has no role in treating systemic hormonal withdrawal symptoms. * **Option B (Calcium and Vitamin D):** While important for bone health in postmenopausal women, these supplements do not treat vasomotor symptoms or irritability. * **Option D (Bisphosphonates):** These are used to treat osteoporosis by inhibiting osteoclast activity. They do not address the hormonal deficiency causing hot flushes. **Clinical Pearls for NEET-PG:** * **Indication:** The primary indication for HRT is the relief of vasomotor symptoms (not the prevention of CHD). * **Route:** Transdermal estrogen is preferred in women with hypertension, smoking, or risk of VTE (bypasses first-pass metabolism). * **Contraindications:** Undiagnosed vaginal bleeding, history of breast cancer, active VTE, or chronic liver disease. * **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60.

Question 1

In a postmenopausal woman, estrogen therapy is initiated. The risk of which of the following conditions will not be increased?

Accepted Answer

Osteoporosis

Answer

Gallstones

Answer

Endometrial carcinoma

Answer

Breast cancer

Question 2

What is the major source of estrogen in postmenopausal women?

Accepted Answer

Peripheral conversion of androstenedione

Answer

Secretion from the adrenals

Answer

Ovarian secretion of testosterone

Answer

None of the above

Question 3

Hormone replacement therapy is contraindicated in which of the following conditions?

Accepted Answer

Thromboembolism

Answer

Atherosclerosis

Answer

Osteoporosis

Answer

Gall stones

Question 4

Which of the following is NOT true about hot flushes?

Accepted Answer

Systolic blood pressure drops during a hot flush.

Answer

Hot flushes typically last for 1 to 5 minutes.

Answer

Skin temperature rises due to peripheral vasodilation.

Answer

Heart rate rises during a hot flush.

Question 5

A vaginal smear from an elderly woman shows atrophic changes. Which type of cells are predominantly seen in such a smear?

Accepted Answer

Basal and parabasal cells

Answer

Atrophic cells

Answer

Superficial cells

Answer

Few intermediate cells

Question 6

Postmenopausal bleeding is most commonly due to:

Accepted Answer

Carcinoma cervix

Answer

Fibroid

Answer

Endometriosis

Answer

Genital TB

Question 7

A 65-year-old female presents with postmenopausal bleeding. On examination, senile vaginitis is noted. The patient requires immediate:

Accepted Answer

Estrogen therapy and colposcopy

Answer

Cytology and colposcopy

Answer

Cytology and fractional curettage

Answer

Fractional curettage

Question 8

All of the following parameters increase in post-menopausal women except?

Accepted Answer

Antithrombin

Answer

Plasminogen activator inhibitor-1

Answer

Factor VII

Answer

Fibrinogen

Question 9

A patient is at risk of estrogen-dependent carcinoma, and thus estrogen is contraindicated. To prevent vasomotor symptoms, which drug is given?

Accepted Answer

Clonidine

Answer

Tamoxifen

Answer

Conjugated estrogen

Answer

Yombinine

Question 10

A 56-year-old woman presents with hot flushes, irritability, joint pains, and insomnia. What is the most appropriate treatment?

Accepted Answer

Combined estrogen, progesterone preparations

Answer

Hysterectomy

Answer

Calcium and vitamin supplementation

Answer

Bisphosphonates

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?